Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Biotest, Nabi deal

BIO will acquire NABI's Nabi Biologics group for $185 million in cash. BIO said the group complements its European plasma protein business and gives it a presence in the U.S. immunoglobulin market. BIO gets NABI's Nabi-HB

Read the full 366 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers